# Extensive-stage small cell lung cancer (ES-SCLC)

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/extensive-stage-small-cell-lung-cancer-es-sclc
Canonical HTML page: https://gethealthbrief.com/entity/extensive-stage-small-cell-lung-cancer-es-sclc

## Timeline

- **2026-07-21**: Partnership Announcement — Menarini Asia-Pacific and Pharmacosmos announce exclusive licensing and distribution agreement for Cosela in 11 APAC markets.

## Recent coverage (1 stories)

### Menarini to Launch First-in-Class CIM Protection Drug Across 11 Asian Markets
2026-07-27 11:19:19 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Menarini Asia-Pacific partners with Pharmacosmos to bring Cosela, a first-in-class myeloprotective drug, to 11 APAC markets. The deal expands access to supportive oncology care, potentially reducing chemotherapy complications and hospitalizations across the region.
Full story: https://gethealthbrief.com/story/menarini-pharmacosmos-cosela-asia-partnership-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.